Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)

  • STATUS
    Recruiting
  • End date
    Jan 11, 2023
  • participants needed
    108
  • sponsor
    Institut fuer Frauengesundheit
Updated on 12 September 2021
measurable disease
AKT
pertuzumab
HER2
trastuzumab
erbb2
her2/neu-positive breast cancer
mammogram
core needle biopsy

Summary

The treatment of patients with HER2 positive early breast cancer has continuously improved over the last decades. Up to now both, trastuzumab and pertuzumab are approved in combination with chemotherapy (CTX) not only for the adjuvant but also for the neoadjuvant treatment of early breast cancer patients. A high pCR rate in the neoadjuvant setting was shown in several trials and observational studies with CTX+ trastuzumab and with CTX+ pertuzumab. The efficacy is dependent on a variety of mechanisms including the blocking of the important PI3K/Akt and MAPK pathways, and ADCC (antibody dependent cellular toxicity).

Recently the biosimilar Ontruzant (SB3) has been introduced into the treatment of HER2 positive breast cancer as a biosimilar. Efficacy and toxicity have been shown to be equivalent to the first approved antibody, however, data from the real-world setting have not been published like it has for the originally approved antibody. Therefore, the aim of this study is to establish safety and efficacy for Ontruzant in the real world setting. Patients can be included if they are treated with Ontruzant in the neoadjuvant setting. Additionally, the study will be accompanied by a comprehensive immune monitoring program and biomarker program to explore immune oncology potential for the neoadjuvant treatment.

Details
Condition Breast Cancer Diagnosis, HER2 Positive Breast Cancer, cancer, breast, breast carcinoma, breast tumors, Breast Cancer Female, her2-positive breast cancer, tumor of the breast, her2/neu-positive breast cancer, breast tumor, Breast Cancer
Treatment Chemotherapy, Pertuzumab, Ontruzant
Clinical Study IdentifierNCT05036005
SponsorInstitut fuer Frauengesundheit
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent prior to beginning of trial specific procedures
Subject must be female and aged 18 years on day of signing informed consent
ECOG 0-1
Histologically confirmed, early HER2 positive breast cancer determined by core biopsy of breast tumor lesion
Measurable tumor lesion with a size of 1 cm assessed by sonography or magnetic resonance imaging (MRI) within 28 days prior to entry. In case of inflammatory disease, the extent of inflammation will be measured
Indication for chemotherapy
Multicentric and/or multifocal disease as well as synchronous bilateral breast cancer is eligible as long as one measurable lesion meets all inclusion criteria. The investigator has to determine which lesion will be used for tumor evaluation before initiation of treatment
Complete staging within 8 weeks prior to entry with no evidence of distant disease, including bilateral mammography, breast ultrasound, chest-X-ray (or chest CT-scan), liver ultrasound (or liver CT-scan or liver MRI) and bone scan
Subjects must provide a core biopsy from tumor lesion before first chemotherapy, after 3 cycles of chemotherapy and after last neoadjuvant study treatment for biomarker analyses
Adequate organ function defined as: Absolute neutrophile count 1500/L, Platelets 100 000/L, Hemoglobin 10.0 g/dL or 6.2 mmol/L, Creatinine 1.5 ULN OR measured or calculated creatinine clearance 30 mL/min for participant with creatinine levels >1.5 institutional ULN (GFR can also be used in place of creatinine or CrCl), Total bilirubin 1.5 ULN OR direct bilirubin ULN for participants with total bilirubin levels >1.5 ULN, AST (SGOT) and ALT (SGPT) 2.5 ULN (5 ULN for participants with liver metastases), International normalized ratio (INR) OR prothrombin time (PT) 1.5 ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants, LVEF > 50 %
Female subjects of childbearing potential must have a negative urine pregnancy test within 72 h prior to study entry and be willing to use an adequate method of contraception for course of the study through 7 months after the last dose of trial treatment

Exclusion Criteria

Concurrent participation in a study with an investigational agent/device or within 14 days of study entry
Prior chemotherapy, radiation therapy or small molecule therapy for any reason
Previous malignant disease being disease-free for less than 3 years (except in situ carcinoma of the cervix and basal cell carcinoma of the skin)
Pregnancy or lactation
Prior neoadjuvant therapy
Active infection requiring systemic therapy
History of (non-infectious) pneumonitis that required steroids or current pneumonitis
Active autoimmune disease or other diseases that requires systemic treatment with corticosteroids or immunosuppressive drugs (physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed)
History of primary or acquired immunodeficiency (including allogenic organ transplant)
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Known history of following infections: Human immunodeficiency virus (HIV), History of acute or chronic Hepatitis B or Hepatitis C, has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
Known congestive heart failure > NYHA I and/or coronary heart disease, angina pectoris, previous history of myocardial infarction, uncontrolled or poorly controlled arterial hypertension (e.g. blood pressure >160/90 mmHg under treatment with two or more antihypertensive drugs), rhythm disorders with clinically significant valvular heart disease
Pre-existing motor or sensory neuropathy of a severity grade 2 by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Any other condition in opinion of the investigator that would interfere with applied systemic treatment or other trial procedures
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note